Quinoline derivatives

• US 6,593,343 B2
• Filed: 04/25/2002
• Issued: 07/15/2003
• Est. Priority Date: 07/15/1998
• Status: Expired due to Term

• Current Assignee: Active Biotech AB
• Original Assignee: Active Biotech AB
• Inventors: Hedlund, Gunnar, Fex, Tomas, Björk, Anders, Jönsson, Stig
• Primary Examiner(s): Huang, Evelyn Mei
• Application Number:
  US10/131,176
• Publication Number:
  US 20020173519A1
• Time in Patent Office: 446 Days
• Field of Search: 514/312, 514/232.8, 514/291, 546/155, 546/90, 544/128
• US Class Current: 514/312
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07D 215/56 with oxygen atoms in position 4

Abstract

Compounds of formula (I)

and tautomers thereof are effective for the treatment of mammals suffering from diseases resulting from autoimmunity and pathological inflammation.

Claims

1. N-ethyl-N-(4-trifluoromethyl-phenyl)-1,2-dihydro-4-hydroxy-5-methoxy-1-methyl-2-oxo-quinoline-3-carboxamide, a pharmaceutically acceptable salt or tautomer thereof.

2. A pharmaceutical composition comprising as active ingredient a pharmaceutically effective amount of the compound of claim 1, together with a pharmaceutically acceptable carrier, said pharmaceutical composition being in a unit dosage amount for administration at a daily dose of said compound of 0.0005 mg/kg to about 10 mg/kg body weight.

3. A method of treating a mammal suffering from pathologic inflammation or a disease resulting from autoimmunity comprising administering to said mammal a pharmaceutically effective amount of the compound of claim 1.

4. The method according to claim 3 wherein said mammal is one suffering from multiple sclerosis (MS).

5. The method according to claim 3 wherein said mammal is one suffering from insulin-dependent diabetes mellitus (IDDM).

6. The method according to claim 3 wherein said mammal is one suffering from systemic lupus erythematosus (SLE).

7. The method according to claim 3 wherein said mammal is one suffering from rheumatoid arthritis (RA).

8. The method according to claim 3 wherein said mammal is one suffering from inflammatory bowel disease (IBD).

9. The method according to claim 3 wherein said mammal is one suffering from psoriasis.

10. The method according to claim 3 wherein said mammal is one suffering from an inflammatory respiratory disorder.

11. The method according to claim 3 wherein said mammal is one suffering from atherosclerosis.

12. The method according to claim 3 wherein said mammal is one suffering from stroke.

13. The method according to claim 3 wherein said mammal is one suffering from Alzheimer'"'"'s disease.

14. The method of claim 3 wherein said effective amount in a daily dose is 0.0005 mg/kg to about 10 mg/kg body weight.

15. The method of claim 3 wherein said effective amount in a daily dose is 0.005 to 1 mg/kg body weight.